GSK2392102A

GSK2392102A is an **investigational 4-component Staphylococcal vaccine** developed by GSK. It is designed as a prophylactic vaccine intended for **active immunisation to prevent Staphylococcus aureus infections** in adults, including skin and soft tissue infections (SSTI), surgical site infections (SSI), and bloodstream infections (BSI). The vaccine is a conjugate that targets multiple staphylococcal antigens. Its mechanism involves stimulating the immune response to develop protection against S. aureus, an important pathogen associated with serious and recurrent hospital and community-acquired infections. The vaccine is administered in a 2-dose schedule, and its clinical studies focus on evaluating **safety, reactogenicity, and immunogenicity** in healthy adults. GSK is the primary developer and sponsor of this product. The most recent publicly available data show the program in **Phase 1 clinical trials** for staphylococcal infections[3][1][5].

Other names

Staphylococcal 4-component investigational vaccineStaphylococcal4-component investigational vaccineStaphylococcal-4-component investigational vaccine